BioLineRx Ltd. (BLRX) Given Average Recommendation of “Buy” by Brokerages
BioLineRx Ltd. (NASDAQ:BLRX) has earned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $2.65.
Several research analysts have commented on the company. Zacks Investment Research raised BioLineRx from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating on shares of BioLineRx in a research report on Tuesday, September 26th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $3.00 target price on shares of BioLineRx in a research report on Tuesday, September 12th. ValuEngine lowered BioLineRx from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, Roth Capital set a $3.00 target price on BioLineRx and gave the company a “buy” rating in a research report on Wednesday, August 9th.
BioLineRx (BLRX) traded up 4.400% during trading on Friday, reaching $1.305. The company’s stock had a trading volume of 714,867 shares. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $0.96. The stock’s market cap is $124.78 million. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). Equities analysts forecast that BioLineRx will post ($0.24) earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. Sabby Management LLC purchased a new position in BioLineRx in the first quarter valued at approximately $3,018,000. KCG Holdings Inc. lifted its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 153,687 shares during the last quarter. Renaissance Technologies LLC purchased a new position in BioLineRx in the first quarter valued at approximately $126,000. Finally, Citadel Advisors LLC lifted its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 86,481 shares during the last quarter. Institutional investors and hedge funds own 32.27% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BioLineRx Ltd. (BLRX) Given Average Recommendation of “Buy” by Brokerages” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/biolinerx-ltd-blrx-given-average-recommendation-of-buy-by-brokerages/1611100.html.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.